JAMA Neurology

Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy

4 June, 2020

Bshra Ali A. Alsfouk, PhD; Martin J. Brodie, MD; Matthew Walters, MD; et al

JAMA Neurology February 24, 2020 2020;77(5):574-581. doi:10.1001/jamaneurol.2020.0032

Key Points

Question
Has the overall tolerability of antiseizure medications (ASMs) improved after the introduction of more than a dozen second-generation ASMs in the past 3 decades?

Findings
In this 30-year longitudinal cohort study of 1795 individuals with newly diagnosed and treated epilepsy, the intolerable adverse effect rate observed was not improved despite the increased using of second-generations ASMs.

Meaning
Efficacy and tolerability are 2 sides of the same coin in achieving successful epilepsy treatment; to improve the overall effectiveness of ASM treatment, future drug development should not only focus on seizure control, but also tolerability and safety profile.